[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tace\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tace":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,44,72,98,127,158,181,206,228],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100625066","construction-and-clinical-validation-of-a-predictive-model-for-postoperative-adjuvant-therapy-in-hepatocellular-carcinoma-based-on-whole-slide-digital-pathological-images-and-deep-learning-100625066",false,"NCT07417800","Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning","Inclusion Criteria:\n\n* Histopathologically confirmed hepatocellular carcinoma;\n* Aged more than 18 years;\n* Underwent radical resection of primary liver cancer (R0 resection);\n* Availability of postoperative H\\&E-stained paraffin embedded tissue sections suitable for digital whole-slide imaging;\n* Had complete and accessible clinicopathological data and follow-up data;\n* Has complete and evaluable preoperative and postoperative contrast-enhanced CT or MRI imaging with standardized scanning parameters and no severe artifacts, meeting the quality requirements for radiomic and artificial intelligence analysis.\n\nExclusion Criteria:\n\n* Significant missing clinical or follow-up data;\n* Concurrent primary malignancy in other organs;\n* Positive surgical margin (R1 or R2 resection);\n* Tissue sections of poor quality (e.g., severe fading, folding, damage) unsuitable for digital scanning or analysis;","ALL","18 Years",{"count":18,"type":19},11000,"ESTIMATED","OBSERVATIONAL","Hepatocellular carcinoma (HCC) is a high-mortality global malignancy with a heavy disease burden in China. Although curative surgical resection improves survival for early-stage HCC patients, the 5-year postoperative recurrence rate remains as high as 50%-70%. Postoperative adjuvant TACE and systemic TKIs are standard treatments for high-risk HCC, yet both therapies have prominent drawbacks, including limited response rates, unavoidable toxicities, and inconsistent clinical benefits. Current treatment decisions rely on conventional clinical and pathological features without precise biomarkers, leading to inadequate individualized therapy and wasted medical resources.\n\nTumor immune microenvironment and multimodal imaging-pathological features critically determine HCC treatment sensitivity. Artificial intelligence and deep learning based on preoperative radiomics and postoperative H\\&E whole-slide imaging (WSI) can capture hidden tumor biological characteristics and predict therapeutic responses. However, no validated multimodal AI model is available for predicting postoperative TACE and TKI treatment outcomes in HCC, lacking large-scale multicenter prospective evidence.\n\nThis study aims to construct and validate a multimodal deep learning model integrating preoperative contrast-enhanced CT\u002FMRI, postoperative WSI, pathological reports, and clinical data, to precisely identify HCC patients sensitive to postoperative adjuvant TACE or TKI therapy and optimize individualized treatment strategies.\n\nThis is a hybrid retrospective-training and prospective observational multicenter study with no clinical intervention. A total of 10,000 retrospective HCC surgical patients will be enrolled to develop an AI classification model for predicting responses to four postoperative treatment strategies: surgery alone, surgery plus TACE, surgery plus TACE combined with systemic therapy, and surgery plus exclusive systemic therapy. Subsequently, 1,000 eligible postoperative HCC patients will be prospectively and consecutively enrolled from 10-15 centers. The AI model will generate adjuvant therapy predictions without interfering with real clinical decisions. Patients will be divided into prediction-consistent and prediction-inconsistent cohorts based on the match between model predictions and actual treatments. Long-term follow-up will be performed to compare prognostic outcomes and validate the model's real-world performance and stability.\n\nKey inclusion criteria: histopathologically confirmed HCC; aged 18-75 years; received R0 curative resection; available qualified H\\&E-stained FFPE slides for digital scanning; complete clinical, pathological and follow-up data; high-quality preoperative contrast-enhanced CT\u002FMRI images eligible for AI analysis. Key exclusion criteria: prior preoperative anti-tumor therapy with unavailable baseline data; concurrent other primary malignancies; non-R0 resection; unqualified pathological slides or imaging data; severe missing clinical or follow-up information.",[23,24,25,26,27,28],"Hepatocellular Carcinoma (HCC)","Artificial Intelligent","Adjuvant Chemoradiotherapy","TACE","Lenvatinib","Liver Surgery",[23,24,26,30,25],"lenvatinib","RECRUITING","2026-06-07",{"date":34,"type":35},"2026-06-10","ACTUAL",{"date":37,"type":35},"2025-11-01",{"date":39,"type":19},"2029-12-01",{"name":41,"class":42},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":43},"100617763","phase-3-deb-tace-vs-ctace-in-hcc-after-tips-100617763","NCT07322848","DEB-TACE vs cTACE in HCC After TIPS","Drug Eluting Beads Transarterial Chemoembolization Versus Conventional Transarterial Chemoembolization for Beyond-Milan-Criteria Hepatocellular Carcinoma After Transjugular Intrahepatic Portosystemic Shunt: A Phase 3, Open Label, Multicenter, Randomized Controlled Trial","UPGRADE","Inclusion Criteria:\n\n1. histologically or clinically confirmed primary hepatocellular carcinoma, beyond Milan criteria (single lesion \\>5 cm OR ≥3 lesions with at least one ≥3 cm). At least one intrahepatic measurable lesion with tumor burden ≤50%, no distant metastasis. No prior antitumor therapy within 12 months before enrollment.\n2. underwent TIPS procedure for secondary prevention of variceal bleeding or refractory ascites. Confirmed patent TIPS at 1-month follow-up with portosystemic blood flow visible throughout the shunt and Doppler velocity \\> 60 cm\u002Fs.\n3. child-Pugh class A or B.\n4. estimated survival ≥3 months.\n5. adequate organ function:Neutrophils ≥1.5 × 10⁹\u002FL; Platelets ≥50 × 10⁹\u002FL; Hemoglobin ≥90 g\u002FL; Serum albumin ≥30 g\u002FL; Bilirubin ≤50 μmol\u002FL; AST\u002FALT ≤5 × upper limit of normal (ULN), ALP ≤4 × ULN; INR ≤2.3; Creatinine ≤1.5 × ULN.\n\nExclusion Criteria:\n\n1. diffuse hepatic infiltration, unassessable lesions on imaging, or tumor burden \\>50%.\n2. simultaneous portal vein branch tumor thrombus or main portal vein tumor thrombus.\n3. underwent liver transplantation or antitumor therapy after TIPS placement.\n4. contraindications to TACE (e.g., portosystemic shunt, hepatofugal blood flow, significant atherosclerosis).\n5. presence of brain metastases.\n6. Allergy to contrast agents.\n7. pregnancy, breastfeeding, or planning pregnancy within 2 years.\n8. co-infection with HIV or syphilis.\n9. concurrent other malignancy or history of other malignancy within the past 5 years.\n10. severe cardiac, renal, or other organ dysfunction.\n11. active clinically severe infection \\> Grade 2 (per NCI-CTC v5.0).\n12. psychiatric\u002Fpsychological conditions that may impair informed consent.\n13. participation in other drug clinical trials within 12 months prior to enrollment.","75 Years",{"count":54,"type":19},206,"INTERVENTIONAL",[57],"PHASE3","This is a Phase 3, open-label, multicenter, randomized controlled clinical trial designed to evaluate the efficacy and safety of Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE) compared with Conventional Transarterial Chemoembolization (cTACE) in patients with hepatocellular carcinoma (HCC) that is beyond the Milan criteria and who have previously undergone a Transjugular Intrahepatic Portosystemic Shunt (TIPS) procedure. The TIPS procedure is commonly performed to manage complications of portal hypertension, such as variceal bleeding or refractory ascites, in patients with cirrhosis. However, after TIPS, treatment options for HCC-particularly in cases exceeding the Milan criteria-remain limited and not well-defined in current guidelines.\n\nWhile TACE is a standard locoregional therapy for intermediate-stage HCC, its application in patients with a prior TIPS is controversial due to altered hepatic hemodynamics, which may increase the risk of liver toxicity and compromise treatment safety and efficacy. Preliminary retrospective data suggest that DEB-TACE, which uses calibrated drug-eluting microspheres, may offer a safer and more effective alternative to cTACE in this specific patient population by providing more controlled drug delivery and potentially reducing systemic and hepatic toxicity.\n\nThe primary objective of this study is to determine whether DEB-TACE improves Overall Survival (OS) compared to cTACE in patients with beyond-Milan HCC after TIPS. Secondary objectives include comparing the safety profile, Progression-Free Survival (PFS), Objective Response Rate (ORR), Disease Control Rate (DCR), and Quality of Life (QoL) between the two treatment arms.\n\nThe study aims to enroll 206 participants who will be randomly assigned in a 1:1 ratio to receive either DEB-TACE or cTACE. The trial will include a 24-month recruitment period and a 24-month treatment and follow-up phase, with a total study duration of 48 months. By directly comparing these two TACE approaches in a prospectively defined and randomized setting, this study seeks to provide high-level evidence to guide the optimal locoregional treatment strategy for HCC patients with a history of TIPS placement.",[23,26,60,61,62],"TIPS","DEB-TACE","cTACE","2026-04-27",{"date":65,"type":35},"2026-05-01",{"date":67,"type":35},"2025-12-01",{"date":69,"type":19},"2029-12-31",{"name":71,"class":42},"First Affiliated Hospital, Sun Yat-Sen University",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":55,"phases":82,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":4},"100623594","phase-2-h101-plus-tace-for-rm-hnscc-100623594","NCT07398664","H101 Plus TACE for r\u002Fm HNSCC","Recombinant Human Adenovirus 5 (H101) Combined With Transcatheter Arterial Chemoembolization (TACE) for the Treatment of Recurrent\u002FMetastatic Head and Neck Squamous Cell Carcinoma: A Single-Center, Prospective Study","Inclusion Criteria:\n\n1. Age between 18 and under 80 years old.\n2. Pathologically confirmed head and neck malignancies (including nasopharyngeal carcinoma, oral cavity cancer, oropharyngeal cancer, laryngeal cancer, hypopharyngeal cancer, salivary gland cancer, nasal cavity and paranasal sinus cancer, etc.); patients who have failed at least two lines of standard treatment (including cetuximab and immuno check point inhibitors).\n3. Expected survival ≥3 months.\n4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0-2.\n5. Pre-treatment peripheral blood tests meet the following conditions: neutrophil count \\>2000\u002Fmm³, platelet count \\>100,000\u002Fmm³.\n6. Pre-treatment liver and kidney function meet the following: bilirubin \\\u003C1.5 mg\u002FdL, AST or ALT \\\u003C1.5 times the upper limit of normal, serum creatinine \\\u003C1.5 mg\u002FdL, creatinine clearance \\>60 mL\u002Fmin.\n7. Agreement to follow the trial treatment plan and visit schedule, voluntary participation, and written informed consent.\n\nExclusion Criteria:\n\n1. Expected survival less than 3 months.\n2. Positive pregnancy test for women of childbearing age.\n3. Concurrent diseases or conditions that affect the patient's ability to enroll normally or safety during the study period.\n4. Active psychiatric disorders or other psychological conditions that affect the patient's ability to sign the informed consent or understand the study.\n5. Severe coagulation abnormalities and\u002For active infection requiring intravenous anti-infective therapy.\n6. History of another malignancy within 5 years prior to screening, except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or microscopic papillary thyroid carcinoma that have been treated with potential curative therapy.\n7. Severe cardiac arrhythmia or conduction abnormalities, and clinically uncontrolled hypertension (systolic blood pressure \\>150 mmHg and\u002For diastolic blood pressure \\>90 mmHg).\n8. Adverse reactions from prior anti-tumor treatments have not recovered to CTCAE version 5.0 Grade \\\u003C1 (except for toxicities judged by the investigator to pose no safety risk, such as alopecia, Grade 2 peripheral neuropathy, etc.).\n9. History of infectious diseases, such as positive HIV antibody test, active hepatitis B (defined as HBsAg positive during screening, with HBV-DNA levels above the upper limit of normal at the local laboratory), or hepatitis C (defined as positive HCV-Ab test during screening with positive HCV-RNA).\n10. Other conditions considered by the investigator to potentially affect patient compliance or make the patient unsuitable for participation in this study.","80 Years",{"count":81,"type":19},20,[83],"PHASE2","This study evaluates H101 combined with transarterial chemoembolization (TACE) to enhance local tumor killing and immune activation while minimizing toxicity in r\u002Fm HNSCC patients.",[86,87,26],"Head and Neck Squamous Cell Carcinoma","Oncolytic Virus","NOT_YET_RECRUITING","2026-02-07",{"date":91,"type":35},"2026-02-10",{"date":93,"type":19},"2026-02-15",{"date":95,"type":19},"2028-02-15",{"name":97,"class":42},"West China Hospital",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":79,"enrollmentInfo":105,"targetDuration":4,"studyType":55,"phases":107,"briefSummary":108,"conditions":109,"keywords":113,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":43},"100607289","phase-3-adjuvant-radiotherapy-of-sintilimab-versus-tace-for-hcc-100607289","NCT07186621","Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC","Adjuvant Radiotherapy Combined With Sintilimab Versus Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma With Narrow Margins and High-Risk Features Following Resection: A Multi-center Phase III Randomized Controlled Trial","Inclusion Criteria:\n\n1. R0 resection of hepatocellular carcinoma (HCC) with a surgical margin \\\u003C1 cm (determined by postoperative pathology, surgical records, and imaging).\n2. Within 4 months after curative resection.\n3. High-Risk Recurrence Factors (at least one required in addition to narrow margin): (1) Microvascular invasion (MVI) positive, tumor thrombus, or satellite nodules (2) Preoperative AFP \\>400 ng\u002FmL (3) Tumor \\>5 cm with incomplete capsule\n4. ≥18 and ≤80 years old.\n5. ECOG score 0-1.\n6. Child-Pugh Class: A5, A6, or B7.\n7. Postoperative Contrast-enhanced MRI of the liver must be performed to exclude intrahepatic residual lesions.\n8. HBV DNA and HCV RNA status do not affect eligibility, but if HBV DNA positive and\u002For HCV RNA positive: ALT must be \\\u003C1.5× upper limit of normal (ULN). Antiviral therapy must be initiated.\n9. Liver Function Tests (LFTs): ALT ≤2.5× ULN (if HBV\u002FHCV positive, ALT ≤1.5× ULN). If ALT ≤1.5× ULN, AST ≤6× ULN (excluding AST elevation due to myocardial infarction). If ALT 1.5-2.5× ULN, AST ≤2.5× ULN.\n10. No significant ECG abnormalities and no severe cardiac dysfunction.\n11. Serum creatinine (CRE) and BUN ≤2.5× ULN.\n12. Hb≥80g\u002FL，ANC≥1.0×109 \u002FL，PLT≥40×109 \u002FL.\n13. Written informed consent obtained.\n\nExclusion Criteria:\n\n1. Vp3 or Vp4 portal vein tumor thrombus (PVTT) or Vv2\u002FVv3 inferior vena cava (IVC) tumor thrombus on preoperative imaging.\n2. Previous anti-HCC therapies, including but not limited to: targeted therapy (e.g., tyrosine kinase inhibitors), immune checkpoint inhibitors (e.g., PD-1\u002FPD-L1 inhibitors) or systemic chemotherapy\n3. Distant metastasis before randomization.\n4. Moderate to severe ascites unresponsive to medical management.\n5. History of other malignancies, except: carcinoma in situ，early-stage papillary thyroid cancer or basal cell carcinoma of the skin\n6. Previous radiotherapy involving the abdomen.\n7. Significant cardiac, renal, or other major organ dysfunction.\n8. Active Autoimmune Disease or Psychiatric Disorders.\n9. HIV Infection.\n10. Pregnant or breastfeeding women.\n11. Currently enrolled in another interventional clinical trial.",{"count":106,"type":19},286,[57],"This study is an open-label, randomized controlled, multicenter, phase III clinical trial",[23,110,111,26,112],"Radiotherapy, Adjuvant","Immune Checkpoint Inhibitor","Narrow Margin",[114,115,116,117,26],"hepatocellular carcinoma","radiotherapy","narrow margin","sintilimab","2025-09-16",{"date":120,"type":35},"2025-09-22",{"date":122,"type":35},"2025-07-10",{"date":124,"type":19},"2028-11-30",{"name":126,"class":42},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":135,"sex":15,"minAge":136,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":55,"phases":139,"briefSummary":140,"conditions":141,"keywords":145,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":4},"100605910","phase-2-partial-immune-boost-tace-in-unresectable-hcc-patients-under-systemic-treatment-100605910","NCT07168668","Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment","Exploring Clinical Efficacy of Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment (EXEPECT Trial)","EXEPECT","inclusion criteria:\n\n1. Participants must have diagnosis of HCC that is deemed unsuitable for surgical resection or transplant. Participants may have multiple lesions with a total maximal tumor dimension of \\\u003C 20 cm, and no one lesion \\> 15 cm. Diagnosis should be confirmed by at least 1 criterion listed below:\n\n   Histologically or cytologically proven diagnosis of HCC. Typical arterial enhancement and delayed washout on multiphasic CT or MRI.\n2. Age ≥18 years at the time of signing informed consent document.\n3. ECOG performance status 0-1.\n4. Barcelona Clinic Liver Cancer (BCLC) stages B or C.\n5. Child-Pugh score 5-6 liver function within 28 days of study registration.\n6. Documented virology status of hepatitis B virus (HBV), as confirmed by screening HBV serology test.\n7. Documented virology status of hepatitis C virus (HCV), as confirmed by screening HCV serology test.\n8. Ability to understand and the willingness to sign a written informed consent document\n9. Adequate bone marrow, liver, and renal function within 4 weeks before study registration\n\n   * Hemoglobin ≥ 9.0 g\u002FdL\n   * Absolute neutrophil count (ANC) ≥ 1,000\u002Fmm3\n   * Platelet count ≥ 50,000\u002FμL\n   * Total bilirubin \\\u003C 2.5 mg\u002FdL\n   * Serum albumin \\>2.8 g\u002FdL\n   * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × upper limit of normal (ULN)\n   * Prothrombin time ≤ 6 seconds prolonged\n   * Serum creatinine ≤ 1.5 mg\u002FdL\n\nExclusion Criteria:\n\n1. Prior invasive malignancy unless disease free for a minimum of 2 years\n2. Prior radiotherapy to the region of the liver that would result in overlap of embolization fields\n3. Prior selective internal radiotherapy\u002Fhepatic arterial yttrium therapy, at any time\n4. Untreated active hepatitis B or hepatitis C\n5. Moderate to severe or intractable ascites\n6. Untreated or incomplete treated esophageal or gastric varices\n7. Severe, active co-morbidity, defined as follows:\n\n   * Unstable angina and\u002For congestive heart failure requiring hospitalization within the last 6 months prior to registration\n   * Myocardial infarction within the last 6 months prior to study entry\n   * Acute bacterial or fungal infection requiring intravenous antibiotics within 28 days prior to study entry\n   * A bleeding episode within 6 months prior to study entry due to any cause. o Thrombolytic therapy within 28 days prior to study entry.\n   * Known bleeding or clotting disorder.\n   * Uncontrolled psychotic disorder\n8. Pregnancy or women of childbearing potential and men who are sexually active and not willing\u002Fable to use medically acceptable forms of contraception\n9. Prior solid organ transplantation.\n10. Prior or active autoimmune disease (AID) including autoimmune hepatitis, inflammatory bowel disease, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjogren's syndrome, Guillain-Barre syndrome, and multiple sclerosis.\n11. Prior or active thrombotic or bleeding disorders, hemoptysis, cerebral vascular accident, significant cardiac disease (ischemic or congestive heart failure), or gastrointestinal perforation.\n12. Known HIV infection.",true,"20 Years",{"count":138,"type":19},90,[83],"Study Objectives： Atezolizumab (anti-programmed death-ligand 1; anti-PD-L1) combined with bevacizumab (anti-vascular endothelial growth factor; anti-VEGF) or Durvalumab (anti-programmed death-ligand 1; anti-PD-L1) combined with tremelimumab (anti-cytotoxic T-lymphocyte-associated protein 4; anti-CTLA4) have recently been established as a standard first-line systemic treatment for unresectable hepatocellular carcinoma (HCC). However, its objective response rate (ORR) is only less than 27% (1, 2), and the majority of patients died of HCC progression and liver failure. Therefore, there is an urgent need to develop a novel combination treatment strategy to overcome resistance to immunotherapy and improve patient outcomes.\n\nTransarterial chemoembolization (TACE) remains the standard treatment for patients with intermediate-stage hepatocellular carcinoma (HCC) (3, 4). However, in our previous retrospective study (5-7), the investigators consistently observed that this combination not only improves therapeutic responses but also significantly prolongs patient survival. The tumor necrosis caused by TACE may enhance the efficacy of systemic therapies by promoting the release of neoantigens, thereby stimulating immune responses (8-14). This concept has been substantiated in two recent trials involving intermediate-stage HCC (15, 16), where the addition of immune checkpoint inhibitors to TACE resulted in improved clinical outcomes. Nevertheless, this promising approach has yet to replace the decades-old standard treatment protocols, underscoring the need for further proof-of-concept studies.\n\nBoth immunotherapy (atezolizumab\u002Fbevacizumab or durvalumab\u002Ftremelimumab) and transarterial chemoembolization (TACE) are approved treatment modalities for unresectable hepatocellular carcinoma (HCC) by the U.S. and Taiwan Food and Drug Administration (FDA). This phase II non-randomized trial is designed to prospectively evaluate the therapeutic efficacy, safety, and immunological responses in patients with unresectable HCC treated with a combination of immunotherapy and TACE. A particular focus of this study is to explore the potential immune-boosting effects of TACE, including its ability to enhance antigen presentation and stimulate anti-tumor immune responses.",[142,143,144],"HCC","Tace","Immunotherapy",[146,147,148],"hepatocelluar carcinoma","transarterial chemoembolization","immunotherapy","2025-09-04",{"date":151,"type":35},"2025-09-11",{"date":153,"type":19},"2025-09-15",{"date":155,"type":19},"2028-05-30",{"name":157,"class":42},"Chang Gung Memorial Hospital",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":52,"enrollmentInfo":164,"targetDuration":4,"studyType":55,"phases":166,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":4},"100602802","phase-2-a-single-arm-multicenter-exploratory-clinical-study-of-transarterial-chemoembolization-tace-combined-with-iparomlimab-and-tuvonralimab-injection-and-bevacizumab-injection-for-the-treatment-of-unresectable-non-metastatic-hepatocellular-carcinoma-hcc-100602802","NCT07128251","A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)","Inclusion Criteria:\n\n1. Voluntarily participate in the study and provide written informed consent.\n2. Age 18-75 years, inclusive (male or female).\n3. Histologically or cytologically confirmed HCC, or clinically diagnosed HCC according to the \\*Clinical Practice Guidelines for Primary Liver Cancer (2024 Edition)\\*.\n4. Barcelona Clinic Liver Cancer (BCLC) Stage A, B, or C, not amenable to curative treatment (e.g., surgical resection, liver transplantation, or ablation).\n5. At least one measurable lesion according to RECIST v1.1 criteria.\n6. Suitable candidate for Transarterial Chemoembolization (TACE) with no known allergy or contraindication to iodized oil or epirubicin.\n7. Child-Pugh Liver Function Class A.\n8. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.\n9. Life expectancy ≥ 3 months.\n10. Adequate organ and bone marrow function.\n11. If positive for Hepatitis B Virus (HBV) infection, HBV DNA must be \\\u003C 2000 IU\u002FmL (\\\u003C 10,000 copies\u002FmL if only copies\u002FmL units available at the site) and the subject must be willing to receive continuous antiviral therapy throughout the study period. Subjects positive for Hepatitis C Virus (HCV) RNA must receive antiviral therapy according to clinical guidelines.\n12. Subjects with esophageal\u002Fgastric varices must undergo evaluation and appropriate management prior to enrollment.\n13. Women of childbearing potential (WOCBP): Must have a negative serum human chorionic gonadotropin (hCG) test within 7 days prior to initiation of study treatment; must be non-lactating; must agree to use highly effective contraception methods from signing informed consent until 120 days after the last dose of study treatment. A woman is considered of childbearing potential if she is postmenarchal, has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (hysterectomy, bilateral salpingectomy\u002Foophorectomy). Male subjects with female partners of childbearing potential: Must agree to use highly effective contraception methods from signing informed consent until 120 days after the last dose of study treatment; must agree to refrain from sperm donation. Male subjects with pregnant partners must use condoms; no additional contraception is required.\n\nExclusion Criteria:\n\n1. Known fibrolamellar HCC, sarcomatoid HCC, mixed hepatocellular cholangiocarcinoma, or cholangiocarcinoma; history of other active malignancies within 5 years or concurrently with HCC. Cured localized tumors (e.g., basal cell carcinoma, squamous cell carcinoma of the skin, superficial bladder carcinoma, carcinoma \\*in situ\\* of the prostate, cervix, or breast) are permitted.\n2. Presence of Vp3 or Vp4 portal vein tumor thrombosis (PVTT), any grade of hepatic vein or inferior vena cava invasion; any grade of bile duct invasion. \\*Note: Vp1 or Vp2 PVTT is permitted.\\*\n3. Presence of extrahepatic spread (EHS).\n4. Intrahepatic lesion(s) with maximum diameter ≥ 10 cm, \\> 10 intrahepatic lesions, or intrahepatic tumor burden ≥ 70% of liver volume, per RECIST v1.1.\n5. Prior systemic anti-cancer therapy for HCC, including molecular targeted agents, cytotoxic chemotherapy, immunotherapy (e.g., immune checkpoint inhibitors, immune checkpoint agonists, cellular therapies), or biologic therapy (e.g., cancer vaccines, cytokines, growth factors).\n6. Prior locoregional therapy for HCC, including therapeutic TACE, transarterial embolization (TAE), hepatic arterial infusion chemotherapy (HAIC), transarterial radioembolization (TARE).\n\n1\\) Prior curative surgery or ablation is permitted; one session of prophylactic TACE following curative resection is permitted.\n\n2\\) Prior percutaneous ethanol injection (PEI) or radiotherapy with curative intent is permitted.\n\n7\\. Prior or planned organ transplantation or allogeneic bone marrow transplantation.\n\n8\\. Current interstitial lung disease (ILD)\u002Fpneumonitis, history of ILD\u002Fpneumonitis requiring steroid treatment, or other pulmonary conditions that may interfere with the detection or management of immune-mediated pneumonitis (e.g., pulmonary fibrosis, organizing pneumonia \\[e.g., bronchiolitis obliterans\\], pneumoconiosis, drug-induced pneumonitis, idiopathic pneumonitis, or active pneumonia evidenced by screening chest computed tomography \\[CT\\] scan). Prior radiation pneumonitis within the radiation field is permitted. Active tuberculosis.\n\n9\\. Active autoimmune disease or history of autoimmune disease with potential for recurrence (e.g., autoimmune hepatitis, interstitial pneumonitis, uveitis, colitis, hypophysitis, vasculitis, nephritis, hyperthyroidism; subjects with hypothyroidism stable on hormone replacement are eligible). Conditions not requiring systemic therapy (e.g., vitiligo, psoriasis, alopecia), controlled Type I diabetes on insulin, or childhood asthma in complete remission without adult intervention are permitted. Asthma requiring bronchodilator therapy is excluded.\n\n10\\. Clinically significant ascites requiring therapeutic paracentesis or drainage (Child-Pugh score \\>2 for ascites; asymptomatic ascites detected only radiographically is permitted); uncontrolled or moderate\u002Flarge pleural effusion or pericardial effusion.\n\n11\\. Uncontrolled hypertension (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg based on ≥2 measurements) despite antihypertensive therapy; history of hypertensive crisis or hypertensive encephalopathy.\n\n12\\. Clinically significant cardiac disease. 13. History of spontaneous rupture of hepatic tumor(s). 14. History of hepatic encephalopathy. 15. History or presence of central nervous system metastases. 16. Congenital or acquired immunodeficiency (e.g., HIV infection). 17. Thromboembolic event within 3 months prior to treatment (e.g., cerebrovascular accident \\[including transient ischemic attack, cerebral hemorrhage, cerebral infarction\\], deep vein thrombosis, pulmonary embolism).\n\n18\\. History of gastrointestinal (GI) bleeding within 6 months prior to treatment or high risk of GI bleeding (e.g., high-risk or severe esophageal\u002Fgastric varices, active GI ulceration, persistent fecal occult blood positivity). \\*Note: If fecal occult blood positive at baseline, repeat test; if persistently positive, esophagogastroduodenoscopy \\[EGD\\] required; exclusion if EGD shows varices\u002Flesions with bleeding risk.\\* 19. Abdominal fistula, GI perforation, intra-abdominal abscess, or bowel obstruction within 6 months prior to treatment.\n\n20\\. Major surgical procedure within 4 weeks prior to treatment or anticipated during study; unhealed wound, ulcer, or fracture within 4 weeks prior to treatment.\n\n21\\. Coagulopathy or bleeding diathesis (e.g., hemophilia); use of antiplatelet agents (e.g., aspirin \\>325 mg\u002Fday, dipyridamole, ticlopidine, clopidogrel, cilostazol) or anticoagulants (e.g., warfarin, low molecular weight heparin) within 10 days prior to treatment.\n\n22\\. Significant vascular disease within 6 months prior to treatment (e.g., aortic aneurysm requiring surgical repair, recent peripheral arterial thrombosis).\n\n23\\. Severe infection within 4 weeks prior to treatment (e.g., requiring hospitalization for infection, bacteremia, or severe pneumonia complications); therapeutic antibiotics administered orally or intravenously within 2 weeks prior to treatment (prophylactic antibiotics, e.g., for UTI or COPD prevention, are permitted).\n\n24\\. Known hypersensitivity to the active substances or excipients of \\*\\*Iparomlimab and Tuvonralimab Injection\\*\\*, \\*\\*Bevacizumab Injection\\*\\*, or epirubicin; history of severe hypersensitivity to any other monoclonal antibody or anti-angiogenic targeted therapy.\n\n25\\. Use of immunosuppressive agents or systemic corticosteroids (\\>10 mg\u002Fday prednisone or equivalent) for immunosuppressive purposes within 2 weeks prior to treatment.\n\n26\\. Administration of live attenuated vaccines within 4 weeks prior to treatment or planned during Iparomlimab and Tuvonralimab Injection treatment or within 60 days after the last dose.\n\n27\\. Treatment with any investigational agent within 4 weeks or 5 half-lives (whichever is longer) prior to treatment initiation.Subjects with any other condition deemed by the investigator to potentially affect study results or lead to premature study termination (e.g., alcoholism, drug abuse, other severe medical\u002Fpsychiatric disorders requiring concomitant therapy, significant laboratory abnormalities, or familial\u002Fsocietal factors compromising subject safety).",{"count":165,"type":19},47,[83],"This is a single-arm, multicenter, exploratory clinical study designed to evaluate the efficacy and safety of TACE combined with Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection in patients with unresectable, non-metastatic HCC. The primary endpoint is PFS as assessed by the investigator based on RECIST v1.1 criteria.",[23,144,169,170,26],"PD-1","CTLA-4","2025-08-13",{"date":173,"type":35},"2025-08-17",{"date":175,"type":19},"2025-08-20",{"date":177,"type":19},"2029-12-30",{"name":179,"class":180},"Anhui Provincial Hospital","OTHER_GOV",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":52,"enrollmentInfo":188,"targetDuration":4,"studyType":55,"phases":190,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":43},"100510009","phase-2-lenvatinib-combined-with-tislelizumab-and-tace-applied-as-neoadjuvant-regimen-for-the-patients-of-cnlc-stage-ib-and-iia-hepatocellular-carcinoma-with-high-risk-recurrence-factors-100510009","NCT05920863","Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors","Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High Risk of Recurrence: Study Protocol of a Monocenter, Single-arm, Open Label Clincal Trail","Inclusion Criteria:\n\n1. Aged 18-75 years old (inclusive);\n2. HCC is confirmed by preoperative pathological examination or meet the criterion of diagnosis and treatment norms of primary HCC issued by health commission, PRC. No prior systemic chemotherapy, immunotherapy, targeted therapy, or other anti-tumor treatments for HCC;\n3. Patients with CNLC IB or IIA stage tumors before surgery and meeting the following conditions: radiological evaluation shows narrow or none surgical margins, and preoperative tumor markers AFP+PIVKA is greater than 1600.\n4. ECOG score of 0 before the first administration of the study drug;\n5. Child-Pugh scores is 5-6 points and liver function is grade A;\n6. Expected survival time of at least 16 weeks;\n7. Pre-administration organ function levels meet the requirements and are tolerant of surgery. The functional indicators of important organs meet the following requirements: hemoglobin ≥90g\u002FL, neutrophil count ≥1.5×10⁹\u002FL, platelet count ≥100×10⁹\u002FL; aspartate aminotransferase or alanine aminotransferase ≤5 times the upper limit of normal (ULN), alkaline phosphatase ≤2.5 ULN, serum albumin ≥30g\u002FL; serum creatinine \\\u003C1.5 ULN; international normalized ratio (INR) ≤2 or prothrombin time (PT) within the upper limit of normal range ≤6 seconds; serum creatinine ≤1.5 ULN, creatinine clearance rate ≥60 mL\u002Fmin.\n8. Male and female participants of childbearing potential must agree to use effective contraception throughout the study period;\n9. Sign an informed consent form and agree to provide previously stored tumor tissue specimens or fresh biopsy specimens of the tumor lesion.\n\nExclusion Criteria:\n\n1. Pathologically diagnosed as non-hepatocellular carcinoma;\n2. Previously received anti-tumor treatments such as chemotherapy, radiotherapy, radiofrequency ablation, intervention, targeted therapy, immunotherapy or surgical treatment for liver cancer (excluding previous non-tumor-related surgery or diagnostic biopsy);\n3. CNLC stage is IA, IIB or worse.\n4. Viral load limited to hepatitis B virus (HBV) DNA\\>2000 copies\u002Fml, hepatitis C virus (HCV) RNA\\>1000;\n5. Long-term steroid users who require long-term systemic steroid therapy (equivalent to \\>10 mg of prednisone per day) or any other form of immunosuppressive treatment;\n6. Significant clinical bleeding or bleeding tendency within 3 months before enrollment or currently undergoing thrombolysis or anticoagulation treatment;\n7. Complete intestinal obstruction and incomplete intestinal obstruction requiring treatment, but patients who have had obstruction relieved by fistula or stent placement can be enrolled;\n8. Active severe clinical infection (\\> grade 2, NCI-CTCAE version 5.0), including active tuberculosis; history of active tuberculosis infection for more than 1 year before enrollment, not treated with regular anti-tuberculosis treatment or tuberculosis still in the active period; active known or suspected autoimmune disease;\n9. Uncontrolled diabetes (fasting blood glucose ≥10 mmol\u002FL), severe lung disease (such as acute pulmonary disease, pulmonary fibrosis that affects lung function, interstitial lung disease. Excluding recovered radiation pneumonitis);\n10. Clinically significant cardiovascular disease; hypertension which cannot be well controlled by anti-hypertensive drugs (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg);\n11. Patients undergoing renal replacement therapy;\n12. History of other malignant tumors within the past 5 years. Excluding cured basal cell carcinoma or cervical intraepithelial neoplasia;\n13. Other patients who are expected to be unable to tolerate surgical treatment;\n14. Patients who have had allergic reactions to any component of the study drug;\n15. Presence of alcohol dependence, mental illness, pregnancy (or lactation) or other conditions that are not suitable for clinical trials.",{"count":189,"type":19},35,[83],"This is a monocenter, single-arm, open-label study to evaluate the efficacy and safety of Lenvatinib combined with Tislelizumab and TACE applied as neoadjuvant regimen for the patients of CNLC stage IB and IIA hepatocellular carcinoma with high risk of recurrence Primary outcome: Major pathological response (MPR) Secondary outcomes: pathological complete response (pCR), R0 resection rate, objective response rate (ORR), disease control rate (DCR), treatment-related adverse events (TRAE)",[193,27,194,26,195,196],"Hepatocellular Carcinoma","Tislelizumab","Pharmorubicin","Oxaliplatin","2025-02-09",{"date":199,"type":35},"2025-02-11",{"date":201,"type":35},"2023-07-01",{"date":203,"type":19},"2025-12-31",{"name":205,"class":42},"Zhejiang Cancer Hospital",{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":215,"conditions":216,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":4},"100553246","prediction-and-prognostic-analysis-of-liver-abscess-formation-after-transcatheter-arterial-chemoembolization-for-hepatocellular-carcinoma-chance-2407-100553246","NCT06483594","Prediction and Prognostic Analysis of Liver Abscess Formation After Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma (CHANCE 2407)","Prediction and Prognostic Analysis of Liver Abscess Formation After Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma : a Retrospective Multicenter Nested Case-control Study (CHANCE 2407)","Inclusion Criteria:\n\n1. Case group inclusion criteria:\n\n   1. Time period of inclusion: 2009-2023 (15 years)\n   2. Patients with HCC diagnosed by clinical or pathological criteria according to the National Health Commission guidelines for the diagnosis and treatment of primary liver cancer who underwent TACE after surgery and developed postoperative liver abscess.\n   3. Appendix: Diagnostic criteria for liver abscess after TACE:\n\n   Condition 1: CT images show typically low-density lesions with or without air and fluid levels\n\n   Condition 2:\n   * positive blood culture\n   * Percutaneous drainage or aspiration is purulent or culture-positive\n   * Symptoms of infection such as fever\u002Fchills, accompanied by elevated inflammatory markers such as white blood cell count, C-reactive protein, or procalcitonin.\n2. Control group inclusion criteria\n\n   1. Patients with HCC without liver abscess who underwent TACE in the same center within the week of treatment in the case group.\n\n      \\-\n\n      Exclusion Criteria:\n\n   \u003C!-- -->\n\n   1. Clinical and follow-up data were incomplete\n   2. Loss to follow-up",{"count":214,"type":19},400,"Liver abscess is a rare but serious complication of hepatocellular carcinoma after TACE, with an incidence of less than 1% reported in previous literature. Studies have shown that history of biliary tract disease, tumor size, embolization materials and embolization endpoint selection may be related to the occurrence of abscess. In recent years, with the wide application of targeted and immune drugs, there have been reports of multiple cases of liver abscess after single target immunotherapy for liver cancer, and there have also been studies showing that TACE combined with targeted immunotherapy can significantly increase the degree of liquefaction necrosis and increase the risk of liver abscess. However, these studies are single-center reports with small sample size and low level of evidence. Therefore, it is of great clinical significance to explore the risk factors of liver abscess after TACE and build a prediction model by using multi-center and large sample data. The formation of liver abscess after TACE means a large range of tissue liquefaction necrosis. There are reports of high incidence of early recurrence and metastasis of liquefaction necrosis. Some studies also show that tumor necrosis is more complete when liver abscess is combined with complete remission. In previous studies, ORR in patients with liver cancer complicated with liver abscess ranged from 18.75%-100%, with significant differences in reports from different centers. The effect of specific abscess formation on TACE efficacy of liver cancer remains to be determined. Therefore, the second research focus of this project is to explore the effect of liver abscess formation after TACE on prognosis of liver cancer.",[26,217,218],"HCC - Hepatocellular Carcinoma","Liver Abscess","2024-06-28",{"date":221,"type":35},"2024-07-03",{"date":223,"type":19},"2024-06-30",{"date":225,"type":19},"2025-06-30",{"name":227,"class":42},"Shengjing Hospital",{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":52,"enrollmentInfo":234,"targetDuration":4,"studyType":55,"phases":236,"briefSummary":237,"conditions":238,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":43},"100513837","phase-2-single-arm-prospective-multicenter-clinical-study-of-tace-with-adebrelimab-and-bevacizumab-for-unresectable-hepatocellular-carcinoma-100513837","NCT05970666","Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma","Inclusion Criteria:\n\n1. Age: 18 \\~ 75, both male and female；\n2. Strictly comply with the primary liver cancer diagnosis and treatment standard (2022 edition) clinical diagnosis criteria or primary hepatocellular carcinoma diagnosed by pathological histology or cytology examination, and at least one measurable lesions (according to the RECIST1.1 standard, the spiral CT scan of 10mm or short diameter of 15mm）；\n3. Patients without previous systematic treatment and inoperable resection \u002F radical ablation surgery, but who can tolerate TACE;\n4. The CNLC stage is Ⅱa-Ⅲb stage;\n5. The Child-Pugh grade of liver function is A grade or B grade (5-7 points);\n6. The ECOG PS score is 0-1 points;\n7. Expected survival period of 12 weeks;\n8. If the patient has active hepatitis B virus (HBV) infection: HBV-deoxyribonucleic acid (DNA) must be \\\u003C2000 IU \u002F mL (if the study site has only copy \u002F mL testing units, Must be \\\u003C12500 copy \u002F mL), And received at least 14 days before initiating anti-HBV treatment (according to local standard therapy, e. g. entecavir) and willing to receive antiviral treatment throughout the study; hepatitis C virus (HCV) ribonucleic acid (RNA) positive patients must receive antiviral treatment according to local standard treatment guidelines and liver function within grade CTCAE 1 elevation;\n9. Main organs function are normal and meet the following criteria: (1) The blood routine examination standards should be met with: (no blood transfusion within 14 days) A. Hemoglobin (HB), 90g \u002F L, B. White blood cell count (WBC) 3109 \u002F L C. Absolute neutrophil count (ANC) 1.5109 \u002F L, D. Platelet (PLT) 80109 \u002F L;(2) Biochemical examination shall meet the following standards: A. Bilirubin (BIL) \\\u003C1.5 times the upper limit of normal value (ULN); B. Glutamic gamma aminotransferase (ALT) and glutamate aminotransferase AST \\\u003C5 ULN; C. Serum creatinine (Cr)≤1.5ULN；\n10. Women of childbearing age must have negative pregnancy test (serum) or urine HCG within 7 days before enrollment and are willing to use appropriate contraception during treatment and 24 weeks after the last administration of test drug; for men, surgical sterilization or agree to use appropriate contraception during and 24 weeks after the last administration of trial drug;\n11. The subjects volunteered to join the study and had good compliance with the follow-up.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women;\n2. The pathology is clearly cholangiocytic carcinoma or mixed cell carcinoma;\n3. Diffuse liver cancer;\n4. Patients with autoimmune diseases, organ \u002F hematopoietic stem cell transplantation or other malignant tumors (except for cured basal skin cell carcinoma and cervix carcinoma in situ);\n5. Patients with consciousness disorders or unable to cooperate with the treatment, combined with patients with mental illness;\n6. Patients who have participated in other clinical trials in the recent three months;\n7. Previous history of other malignancies or have received targeted therapy and other PD-1 \u002F PD-L1 inhibitor therapy;\n8. Received major surgery or chemotherapy or other systemic therapy for target lesions (including not limited to radiation therapy, ablation therapy, etc.) within 1 month prior to enrollment;\n9. Use of immunosuppressants or systemic hormone therapy within 14 days before enrollment to achieve immunosuppressive purposes (dose\\> 10mg \u002F day prednisone or other efficacy hormones);\n10. Liver function was graded as Child-Pugh C, which could not be improved by liver care treatment；\n11. esophageal (gastric fundus) varices rupture and bleeding within 1 month before treatment；\n12. Uncorrectable coagulopathy and severe blood abnormalities, with severe bleeding tendency. Platelet count \\\u003C50109 \u002F L and severe coagulation abnormalities against surgery (anticoagulation therapy and \u002F or anticoagulant therapy should be stopped for more than 1 week before radiation therapy);\n13. A stubborn amount of ascites, pleural fluid, malignant fluid;\n14. Active infection, especially the inflammation of the biliary tract system;\n15. Severe functional failure of the liver, kidney, heart, lung, brain and other major organs;\n16. Previously allergic to PD-1 \u002F PD-L1 mAb \u002F any component of the targeted drug or other similar trials;\n17. Patients with hypertension who cannot be reduced to the normal range by antihypertensive medication (systolic blood pressure\\> 140 mmHg, diastolic blood pressure\\> 90 mmHg);\n18. Previous severe cardiovascular disease, including but not limited to the following diseases: myocardial ischemia or myocardial infarction, poorly controlled arrhythmia (including 450 ms in QTc men and 470 ms in women); cardiac dysfunction by NYHA, or cardiac ultrasound indicating left ventricular ejection fraction (LVEF) \\\u003C50%;\n19. Patients with positive urinary protein (urinary protein test of 2 + or above, or 24-hour urinary protein quantification of\\> 1.0g);\n20. Failure to swallow tablets, malabsorption syndrome, or any condition affecting gastrointestinal absorption;\n21. According to the discretion of the investigator, patients with other concomitant diseases that seriously endanger patient safety or affect the completion of the study;\n22. Patients with radiotherapy, targeted therapy, and other contraindications to immunotherapy.",{"count":235,"type":19},71,[83],"To evaluate the efficacy and safety of TACE combined with adebrelimab and bevacizumab transformation in unresectable hepatocellular carcinoma",[239,193,240,241,26],"Adebrelimab","Transformation","Bevacizumab","2024-02-27",{"date":244,"type":35},"2024-02-28",{"date":246,"type":35},"2023-11-15",{"date":248,"type":19},"2026-11-15",{"name":250,"class":42},"The First Affiliated Hospital of Xiamen University"]